Niacin vs Nicotinamide Riboside
Written by Aaron CuhaReviewed Sep 2026
The short answer
The oldest and the newest NAD building blocks. Niacin is the only compound in this pathway ever tested for heart attacks and strokes, in 29,000 people across two trials, and it prevented none. Nicotinamide riboside has never been tested for a health event of any kind.
- Niacin people
- 29,087
- Niacin nulls
- 0
- Nicotinamide Riboside people
- 90
- Nicotinamide Riboside nulls
- 1
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
Slow-release nicotinic acid is an FDA-approved prescription cholesterol drug in the United States. But doctors mostly stopped using it after two large studies, AIM-HIGH and HPS2-THRIVE. Lower-dose nicotinic acid is also sold over the counter as a supplement. The mix of slow-release niacin and laropiprant tested in HPS2-THRIVE was pulled from sale worldwide after that study reported.
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
4 completed trials, 90 people given it
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
NiacinNicotinic acid, niacin, the acid form of vitamin B3
The only NAD-pathway product ever tested against real heart outcomes, in 25,673 people in HPS2-THRIVE and 3,414 in AIM-HIGH. It moved every blood fat it was meant to move. It prevented no heart attacks or strokes in either study. In HPS2-THRIVE it caused extra serious side effects, including infections and bleeding.
Column B
Nicotinamide RibosideNicotinamide Riboside (NR)
A form of vitamin B3 that reliably raises NAD in people. That part is proven. A big mouse program found it did not help mice live longer.
Side by side, on the facts we can check
| What we compare | Niacin | Nicotinamide Riboside |
|---|---|---|
| Category | Longevity | Longevity |
| FDA status | Slow-release nicotinic acid is an FDA-approved prescription cholesterol drug in the United States. But doctors mostly stopped using it after two large studies, AIM-HIGH and HPS2-THRIVE. Lower-dose nicotinic acid is also sold over the counter as a supplement. The mix of slow-release niacin and laropiprant tested in HPS2-THRIVE was pulled from sale worldwide after that study reported. | Sold as a supplement; not an approved drug |
| Half-life | Under an hour for immediate-release nicotinic acid. Extended-release formulations were built specifically to stretch that out and blunt the flush, and the dose is not interchangeable between forms. | Short |
| Molecular weight | 123.1 Da | 255.2 Da |
| How it works | Niacin gets turned into NAD by its own route, called the Preiss-Handler pathway, not the NAMPT recycling route. That is why it is a strong NAD booster. A 2026 study in people suggested gut bacteria may turn NR and NMN into niacin, and that this may be how those two pricey products work at all. Niacin's effect on blood fats is separate. It mainly slows the release of fat from fat cells and slows fat-making in the liver. So less fat flows to the liver, and the liver sends out fewer fat-carrying particles. The flush is a third, separate action. Niacin switches on a receptor called GPR109A on immune cells in the skin. They release chemicals called prostaglandins that open up the skin's blood vessels. Work in mice with genes switched off proved each link in that chain. The laropiprant in HPS2-THRIVE blocked one of those prostaglandins to stop the flush. It stopped the flush and did nothing for the outcomes. | The body turns NR into NAD through a recycling route. That tops up the NAD that falls with age. NAD feeds the parts of cells that make energy and do repairs. |
| Studies in people | 5 | 5 |
| Evidence | Strong: 2 completed trials, 29,087 people given it | Limited: 4 completed trials, 90 people given it |
| Legal status, US | FDA-approved prescription cholesterol drug, also sold over the counter as a supplement | Sold as a dietary supplement |
Frequently asked questions
What is the difference between Niacin and Nicotinamide Riboside?
Niacin: The only NAD-pathway product ever tested against real heart outcomes, in 25,673 people in HPS2-THRIVE and 3,414 in AIM-HIGH. It moved every blood fat it was meant to move. It prevented no heart attacks or strokes in either study. In HPS2-THRIVE it caused extra serious side effects, including infections and bleeding. Nicotinamide Riboside: A form of vitamin B3 that reliably raises NAD in people. That part is proven. A big mouse program found it did not help mice live longer.
Which has stronger research evidence, Niacin or Nicotinamide Riboside?
Each compound gets a band worked out from facts we counted, with the math shown. Niacin is Strong (2 completed trials, 29,087 people given it). Nicotinamide Riboside is Limited (4 completed trials, 90 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Niacin and Nicotinamide Riboside FDA-approved?
Niacin: Slow-release nicotinic acid is an FDA-approved prescription cholesterol drug in the United States. But doctors mostly stopped using it after two large studies, AIM-HIGH and HPS2-THRIVE. Lower-dose nicotinic acid is also sold over the counter as a supplement. The mix of slow-release niacin and laropiprant tested in HPS2-THRIVE was pulled from sale worldwide after that study reported.. Nicotinamide Riboside: Sold as a supplement; not an approved drug.
Related posts
Blog articles that cover Niacin or Nicotinamide Riboside, newest first.
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.